Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc.

March 26, 2008 17:00 ET

Thallion Redeems All Outstanding Special Preferred Shares

MONTREAL, QUEBEC--(Marketwire - March 26, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that the redemption date of all outstanding special preferred shares of the share capital of the Company was March 25, 2008. As of that date, the special preferred shares - which were issued to former Caprion shareholders as a means to potentially participate in a subsequent sale of certain assets related to Caprion - were automatically redeemed as per the terms and conditions of those special preferred shares. Final proceeds totaling $1.00 has been set aside for redemption of the special preferred shares in relation to this event and all other rights of these special preferred shares have been automatically terminated.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion has three active clinical programs at a Phase II, or later, stage of development which include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anticancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Additional information about the Company can be obtained at

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Contact Information